CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire November 14, 2025 Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated continued best-in-disease durability and tolerability in BOND-003 Cohort C with robust 24-month complete response (CR) rate […]